Heart Failure Co-Morbidities

Waist-to-Height Ratio Outperforms BMI in HFpEF Risk

Radcliffe CVRM

AHA 25: Pregnancy and CKM Health: Essential Knowledge for Cardiologists

Emily Lau

Watch time: 7m 24s
AHA 25 Late-breaking Discussion: Analysis from the SURPASS-CVOT Trial

Harriette Van Spall, Stephen Nicholls

Watch time: 12m 43s
AHA 2025: The TIRZSEMA-CVOT Study

Nils Krüger

Watch time: 5m 49s

Nir Uriel

Watch time: 34m 39s (5 videos)
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF

Barry Borlaug

Watch time: 7m 15s
EASD 25: EMPIRE-PREVENT: Metabolic Effects of Empagliflozin in Patients at Risk of Heart Failure

Camilla Andersen

Watch time: 6m 28s

Shubh K Patel, Hwee Teoh, Ahreni Saunthar, et al

Read time: 24m 34s

Giovanni Battista Bonfioli, Matteo Pagnesi, Daniela Tomasoni, et al

Read time: 15m 45s

Broadcast

Cardiovascular Renal Metabolic

Guidelines & Statements
Targeting Residual Inflammatory Risk

Smeeta Sinha, Ramzi Y. J. Khamis, Daniel Bromage, et al

Managing Obesity in HF: 2025 ACC Scientific Statement

Michelle Kittleson

Watch time: 8m 5s

James Burton, Clara Bonanad Lozano, Csaba Kovesdy, et al

Watch time: 1h 1m 16s (5 videos)

Shubh K Patel, Hwee Teoh, Ahreni Saunthar, et al

Read time: 24m 34s

Broadcast

Cardiovascular Renal Metabolic

Guidelines & Statements
Targeting Residual Inflammatory Risk

Smeeta Sinha, Ramzi Y. J. Khamis, Daniel Bromage, et al

AHA 2025: The TIRZSEMA-CVOT Study

Nils Krüger

Watch time: 5m 49s
AHA 25: Pregnancy and CKM Health: Essential Knowledge for Cardiologists

Emily Lau

Watch time: 7m 24s
AHA 25 Late-breaking Discussion: Analysis from the SURPASS-CVOT Trial

Harriette Van Spall, Stephen Nicholls

Watch time: 12m 43s

Giovanni Battista Bonfioli, Matteo Pagnesi, Daniela Tomasoni, et al

Read time: 15m 45s

James Burton, Clara Bonanad Lozano, Csaba Kovesdy, et al

Watch time: 1h 1m 16s (5 videos)
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF

Barry Borlaug

Watch time: 7m 15s
Waist-to-Height Ratio Outperforms BMI in HFpEF Risk

Radcliffe CVRM

EASD 25: EMPIRE-PREVENT: Metabolic Effects of Empagliflozin in Patients at Risk of Heart Failure

Camilla Andersen

Watch time: 6m 28s

Nir Uriel

Watch time: 34m 39s (5 videos)
Managing Obesity in HF: 2025 ACC Scientific Statement

Michelle Kittleson

Watch time: 8m 5s

Media

Broadcast

Cardiovascular Renal Metabolic

Guidelines & Statements
Targeting Residual Inflammatory Risk

Smeeta Sinha, Ramzi Y. J. Khamis, Daniel Bromage, et al

AHA 2025: The TIRZSEMA-CVOT Study

Nils Krüger

Watch time: 5m 49s
AHA 25: Pregnancy and CKM Health: Essential Knowledge for Cardiologists

Emily Lau

Watch time: 7m 24s
AHA 25 Late-breaking Discussion: Analysis from the SURPASS-CVOT Trial

Harriette Van Spall, Stephen Nicholls

Watch time: 12m 43s

Broadcast

Cardiovascular Renal Metabolic

Heart Failure
Managing Hyperkalaemia: Getting Patients to Optimal RAASi Therapy

James Burton, Clara Bonanad Lozano, Aaron Wong, et al

Watch time: 1h 3m 30s

Nir Uriel

Watch time: 34m 39s (5 videos)

James Burton, Clara Bonanad Lozano, Csaba Kovesdy, et al

Watch time: 1h 1m 16s (5 videos)
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF

Barry Borlaug

Watch time: 7m 15s
EASD 25: EMPIRE-PREVENT: Metabolic Effects of Empagliflozin in Patients at Risk of Heart Failure

Camilla Andersen

Watch time: 6m 28s
Managing Obesity in HF: 2025 ACC Scientific Statement

Michelle Kittleson

Watch time: 8m 5s

Articles

Aldosterone Synthase Inhibitors

Shubh K Patel

,

Hwee Teoh

,

Ahreni Saunthar

,

Terrence M Yau

,

Subodh Verma

,

Published:

18 August 2025

Citation:

Cardiac Failure Review 2025;11:e20.

DOI:

https://doi.org/10.15420/cfr.2025.09
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 939
  • Downloads: Downloads 97
  • Citations: 2
  • Read time: 24m 34s

Understanding the Role of GLP-1 RAs in the Treatment of HF

Giovanni Battista Bonfioli

,

Matteo Pagnesi

,

Daniela Tomasoni

,

Amina Rakisheva

,

Marco Metra

,

Published:

14 August 2025

Citation:

Cardiac Failure Review 2025;11:e19.

DOI:

https://doi.org/10.15420/cfr.2025.10
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 346
  • Downloads: Downloads 66
  • Read time: 15m 45s